The recombinant protein COVID-19 vaccine was approved by the national clinical trial.
Science and Technology Daily, Chengdu, August 23rd (Li Di reporter Li Sheng) The reporter learned from West China Hospital that the recombinant protein COVID-19 vaccine developed by the State Key Laboratory of Biotherapy in our hospital was approved for clinical trial in the State Pharmaceutical Administration on 2 1. The vaccine aims at novel coronavirus, and uses its spike protein receptor binding domain (S-RBD) to produce neutralizing antibodies to prevent the virus from infecting human cells.
The vaccine uses insect cells to propagate in the culture medium, and the gene of novel coronavirus is introduced into the insect cells, and the insect cells are used as? Factory? Produce high quality recombination vaccines protein and purify it. This technology can be easily put into the market on a large scale. It is reported that the recombinant protein vaccine produced by insects has been listed in Europe and America, and its safety to human body has been verified.
The related research paper of this recombinant protein COVID-19 vaccine was published in the journal Nature on July 29th. According to the paper, it was found in animal experiments such as monkeys that the vaccine had a good protective effect on novel coronavirus infection, and no obvious side effects were found.
In April this year, West China Hospital, Chengdu Hi-tech Zone Bio-City and the research team established Chengdu Wesker Biomedical Co., Ltd., and are planning and designing a production line with an annual output of hundreds of millions of doses, which will realize the independent research and development of complete sets of equipment in China. At present, the R&D team is actively promoting the clinical trials of vaccines and settling in Chengdu High-tech Zone to realize industrialization. Besides using insect cells to produce COVID-19 vaccine, the company also uses insect cell technology to produce rabies vaccine, influenza vaccine and herpes virus vaccine. And developed more than 20 innovative immunotherapy products such as various bacterial vaccines and tumor vaccines, and obtained more than 40 related products and technology patents.